Thirty-Day Mortality Rates in Patients with Extended-Spectrum β-Lactamase-Producing <i>Enterobacterales</i> Bacteremia Receiving Ertapenem versus Other Carbapenems-Reference-Cited by-同舟云学术

Thirty-Day Mortality Rates in Patients with Extended-Spectrum β-Lactamase-Producing Enterobacterales Bacteremia Receiving Ertapenem versus Other Carbapenems

Published:2022-07-19 Issue:7 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Park Jin Ju¹,Jung Eun-ju²^ORCID,Kim Jae-Young³,Seo Yu Bin¹^ORCID,Lee Jacob¹,Jung Younghee⁴^ORCID

Affiliation:

1. Kangnam Sacred Heart Hospital, College of Medicine, Hallym University, Seoul, South Korea

2. Dongtan Sacred Heart Hospital, College of Medicine, Hallym University, Hwaseong, South Korea

3. Department of Statistics, Soonchunhyang University Bucheon Hospital, Bucheon, South Korea

4. Hallym University Sacred Heart Hospital, College of Medicine, Hallym University, Anyang, South Korea

Abstract

Ertapenem is one of the carbapenems recommended for treating extended-spectrum β-lactamase (ESBL)-producing Enterobacterales . However, efficacy data are limited.

Funder

National Research Foundation of Korea

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.00287-22

Reference22 articles.

1. Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa)

2. Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae

3. Ertapenem: review of a new carbapenem